



Supplement Figure S3. Inhibition of PC3 prostate cancer cell growth in mice after knockdown ADAM9 expression. (a) Scheme illustration of subcutaneous inoculation of PC3<sub>pSM2C</sub> and PC3<sub>shADAM9</sub> in same mice. PC3<sub>pSM2C</sub> was implanted in the left site and PC3<sub>shADAM9</sub> in the right site of lower back of same mice. (b) Bioluminescence imaging obtained at day-30 post inoculation. Only two mice revealed a weak bioluminescence signal on the right site of PC3<sub>shADAM9</sub> (black arrow). (c) On day 15, signal was first observed at the PC3<sub>pSM2C</sub> implant site in 50% of the mice, increasing to 90% on day 25. The number of mice with a signal at the PC3<sub>shADAM9</sub> implant site remained at 10% (mice, n=20; \*\* p ≤ 0.001). (d) Tumor volume was measured every 5 days starting at day 15 and ending at day 60. Tumor volume was 281 ± 91 mm<sup>3</sup> in PC3<sub>pSM2C</sub> and 140 ± 37 mm<sup>3</sup> in PC3<sub>shADAM9</sub> on day 60 (means ± SD) (\*p ≤ 0.05 one-way ANOVA).